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Implication for health policy/practice/research/medical education:
The results of this study suggest that examining the serum levels of vitamin D allows screening people at risk for metabolic 
syndrome development.
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Introduction: Decreased vitamin D levels may have a role in the development of metabolic 
syndrome due to its effect on the metabolic syndrome components or because of insulin 
resistance.
Objectives: The aim of this study was to investigate the prevalence of vitamin D deficiency 
in obese individuals and to determine the relationship between deficiency of vitamin D with 
metabolic syndrome in obese people with metabolic syndrome and healthy individuals.
Patients and Methods: In this descriptive-analytical study, samples were selected among 
obese individuals admitted to Hajar and Kashani hospitals in Shahrekord. Metabolic indices 
of the samples were measured and recorded along with information such as demographic 
characteristics. According to the indices, the subjects (n= 192) were divided into two equal 
groups of healthy obese and obese people with metabolic syndrome. Vitamin D levels were 
measured in both groups followed by determination of relationships between the vitamin D 
levels with metabolic syndrome and its indices.
Results: The mean ages of the patients and healthy groups were 50.09±1.95 years and 
52.57±2.05 years, respectively. The average serum vitamin D levels in the two groups showed 
a significant difference with significantly lower vitamin D levels in the metabolic syndrome 
group than those in the obese subjects (P < 0.001). The relationship between each of the 
metabolic syndrome indices at different levels of vitamin D showed that levels of triglyceride 
(TG) and fasting blood sugar (FBS) decreased with increasing serum vitamin D. However, the 
level of vitamin D was not significantly related to the waist size and body mass index (BMI) 
(P > 0.05).
Conclusion: The results of this study indicated that vitamin D determination can be used for 
the prognosis and early detection of people at risk for metabolic syndrome.
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Introduction
Metabolic syndrome (insulin resistance syndrome) 
includes a series of metabolic disorders that increase the 
risk of cardiovascular diseases and type II diabetes (1-
3). Following increased urbanization, inactivity, stress, 
and consumption of fatty, high-carbohydrate and high-
calorie foods, the incidence of metabolic syndrome 
has been growing steadily throughout the world over 
the past 20 years, in which up to 25% of the population 
has been involved according to the latest research (4). 
In fact, changes in the lifestyle of people over the past 
decades have contributed to the prevalence of obesity 
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and metabolic syndrome in societies. Along with disease 
complications, special attention to studies on obesity, its 
complications, and related factors has attracted in recent 
years. Although the cause of metabolic syndrome has not 
been fully understood, insulin resistance and visceral fat 
accumulation have been suggested as the underlying causes 
(5). It seems that a combination of genetic, metabolic, and 
environmental factors such as diet have an important 
role in the development of metabolic syndrome (6). 
Some studies have shown that decreased levels of vitamin 
D may be involved in the development of metabolic 
syndrome owing to its effect on each component of the 
metabolic syndrome, or because of insulin resistance (7-
10). However, such a role has not been confirmed in some 
other studies (11,12). 
Objectives
The present study, therefore, aimed to study more precisely 
a possible cause of metabolic syndrome by examining 
the serum levels of vitamin D and its relationship with 
metabolic parameters.
Patients and Methods
Study population
In this descriptive-analytic study, all obese subjects with 
body mass index (BMI) values of ≥25% were randomly 
selected through convenient sampling at Hajar and 
Kashani hospitals in Shahrekord. The inclusion criteria 
were BMI values of ≥ 25 kg/m2, ages of >18 years, and 
presence of metabolic syndrome. The exclusion criteria 
included kidney disease, liver disease, and use of weight 
loss drugs or weight loss efforts. Additionally, vitamin D 
intake, pregnancy, breast feeding, withdrawal from the 
continued cooperation or non-participation in tests and 
examinations, and intake of estrogen and progesterone 
pills in women were the exclusion criteria. Accordingly, 
a total of 192 individuals were selected as the sample size. 
Lipid profile and fasting blood sugar (FBS) of all subjects 
were determined by blood sample tests. Blood glucose was 
measured on the sampling day by enzymatic colorimetry 
using glucose oxidase. Triglyceride levels were measured 
by BIONIK commercial kits with a BT-3000 device by 
cholesterol esterase colorimetric tests, cholesterol oxidase, 
and glycerol phosphate oxidase. The laboratory reported a 
normal cholesterol range of 130-200 mg/dL. Serum HDL 
cholesterol was measured after the precipitation of APoB 
protein lipids using phosphotungstic acid solution. Serum 
LDL cholesterol was assessed after determining total 
cholesterol concentration using the Friedewald formula. 
Serum LDL-C was evaluated by an enzyme kit when serum 
triglyceride levels exceeded 400 mg/dL. All samples were 
evaluated with an acceptable standard after an internal 
quality control. The internal and external changes were 1.6 
and 0.6% for triglyceride (TG), and 2% and 0.5% for total 
cholesterol, respectively. Serum triglyceride levels equal 
to or greater than 150 mg/dL, HDL-C concentrations less 
than 40 mg/dL in men and less than 50 mg/dL in women, 
and fasting glucose values of 100 mg/dL or higher were 
defined according to National Cholesterol Education 
Program (NCEP), Panel III NCEP-ATP III (13). Metabolic 
syndrome was defined by the NCEP-ATP III criteria. 
After identification of subjects with metabolic syndrome, 
they were divided into two groups of 96 patients (those 
with metabolic syndrome during obesity) and 96 healthy 
subjects (those without metabolic syndrome). The two 
groups were selected based on gender, age, occupation, 
physical activity, smoking, type of urban and rural 
populations, and similar education levels.
Blood samples were collected from all participants in the 
study after 12 hours of fasting to measure serum vitamin 
D 25(OH) levels at 8 am. The following vitamin D levels 
were defined based on the laboratory report; vitamin 
D 25 (OH) deficiency when it is less than 20 ng/mL. 
Insufficient vitamin D 25(OH) level; 20-30 ng/mL, and 
toxic doses of vitamin D 25(OH) when it is over 100 ng/
mL. After measuring levels of vitamin D in both groups, 
direct correlations of the vitamin values were determined 
with metabolic syndrome and its indices in obesity.
Ethical issues
1) The research followed the tenets of the Declaration of 
Helsinki; 2) informed consent was obtained; and 3) This 
study was approved by the Ethics Committee of Shahrekord 
University of Medical Sciences. This study is the result of a 
dissertation of Hamid Daemi (MD dissertation).
Data analysis 
Data were entered into an Excel database and then analyzed 
using the SPSS software version 22. Descriptive and 
inferential statistics including mean, standard deviation, 
t test, chi-square, and Pearson’s correlation coefficient was 
conducted by SPSS software. The threshold of P < 0.05 was 
considered significant.
Results
The selected participants (n = 192) in this study had an 
average age of 51.37 ± 19.22 years and were assigned 
to two groups after distribution normality of data was 
confirmed. The first group comprised 96 obese people 
with metabolic syndrome and the second group consisted 
of 96 non-obese subjects with metabolic syndrome. There 
were 40 male smokers, 20 of which were in the metabolic 
syndrome group and 20 individuals in the healthy group 
(Table 1). The metabolic syndrome parameters are 
presented in Table 2.
The prevalence of vitamin D deficiency was 58.85%. A 
mean vitamin D levels of 18.88 ± 1.24 ng/mL was found 
in subjects with metabolic syndrome. The vitamin level in 
the obese group without metabolic syndrome was 40.38 ± 
2.15 ng/mL. The decrease in the mean level of vitamin D 
in our patients was significant when compared to healthy 
participants (P < 0.001). Distribution of vitamin D status 
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in the studied groups is presented in Table 3.
Table 4 shows the comparison of metabolic syndrome 
indices at different levels of vitamin D. The mean serum 
HDL-C level increased with increasing vitamin D levels but 
the mean serum levels of TG, and FBS and systolic blood 
pressure decreased significantly (P < 0.05). However, BMI 
remained almost constant with increasing serum vitamin 
D levels with no significant relationships (P = 0.999). 
Additionally, the waist size was not significantly correlated 
with increased serum vitamin D levels (P = 0.825).
Discussion
The present study aimed to determine the prevalence 
of vitamin D deficiency in obese individuals and the 
relationship between vitamin D deficiency and metabolic 
syndrome with some indices in obese patients with 
metabolic syndrome and healthy subjects. Vitamin D was 
found to be rather highly deficient in the subjects. Serum 
vitamin D levels were significantly lower in the patients 
than in control group. The relationship between each 
of the metabolic syndrome indices at different levels of 
vitamin D showed that levels of TG and FBS decreased 
with increasing serum vitamin D, and that HDL-C levels 
were consistent with vitamin D levels showing significant 
changes. However, the level of vitamin D was not 
significantly correlated with waist and BMI.
The prevalence and incidence of metabolic syndrome is 
increasing worldwide. One of the latest studies in Iran 
reported a metabolic syndrome prevalence of over 30%, 
which was significantly higher in women than in men 
(42% versus 24%) (14). Our results revealed a prevalence 
of 85.58% for vitamin D deficiency. A study by Soltani et 
al reported a prevalence of 62% and 21.2% for vitamin 
D deficiency and metabolic syndrome, respectively (15). 
In addition, Ford et al evaluated a vitamin D deficit 
prevalence of 72% for serum vitamin D and metabolic 
syndrome in a total of 8421 adult Americans (16). In 
another study on 646 Iranian adults, the frequencies 
of metabolic syndrome and vitamin D deficiency were 
detected to be 18.3% and 73.3%, respectively (17). A 
study in South Korea by Park et al revealed a relationship 
between serum vitamin D levels and metabolic syndrome, 
with a 76.6% increased incidence of vitamin D deficiency 
in patients with metabolic syndrome (18). The frequency 
of vitamin D deficiency in our study is lower than those 
found in other studies, which can be due to differences in 
the method of measuring serum vitamin D levels, culture, 
coverage, solar radiation levels, exposure to sunlight, 
sample collection season, and geographical coordinates. 
Our findings also indicate significantly lower serum 
vitamin D levels in the patients than in the normal group. 
Such a significant relationship could be related to the role 
of vitamin D in blood pressure regulation and diabetic 
insulin resistance. This relationship can also depend on 
the degree of mobility and exposure to sunlight. In fact, 
vitamin D is one of the essential fat-soluble vitamins in 
the body that helps bone growth and strength through the 
control of calcium and phosphorus balance. The vitamin 
D increases the absorption of phosphorus and calcium 
from the intestine, thereby, regulate bone metabolism. 
Other studies have also demonstrated that decreased 
vitamin D levels can contribute to the development 
of metabolic syndrome by affecting either metabolic 
syndrome components or through insulin resistance (7). 
Table 1. Demographic data of individuals in the two groups studied
Groups
Age (y) Gender Smoker
Mean± SD MaleNo. (%)
Female
No. (%)
Yes
No. (%)
No
No. (%)
Patients with metabolic syndrome (n=96) 50.09±1.95 52 (54.17) 44 (45.83) 20 (20.83 ) 76 (79.17)
Control (obese individuals without metabolic syndrome; n=96) 52.57±2.05 51 (53.12 ) 45 (46.87) 20 (20.83 ) 76 (79.17)
P value 0.38 0.92 0.82
Table 2. Metabolic syndrome indicators in the studied subjects 
Variables Patients with 
metabolic syndrome
Control (obese individuals 
without metabolic syndrome)
Minimum Maximum Coefficient of 
variation (CV) P value
Length (cm) 161.56±1.82 162.44±1.51 142 185 43 0.71
Weight (kg) 74.91±0.97 74.17±1.03 47.5 105 57.5 0.602
BMI (Kg/m2) 27.95±0.28 27.77±0.27 25 42.66 17.66 0.655
Blood pressure (mm Hg) 137.47±1.74 124.65±1.46 90/60 190/110 100/50 <0.001
Waist size (cm) 95.42±1.02 94.48±0.89 73 117 44 0.49
HDL-C (mg/dL) 42.89±0.56 54.56±1.15 31 63 32 <0.001
TG (mg/dL) 176.51±1.45 145.49±2.07 93 224 131 <0.001
FBS (mg/dL) 128.11±4.60 95.49±1.75 71 312 241 <0.001
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A suggested role for vitamin D is participation of insulin 
synthesis and secretion thus reduced vitamin D levels is a 
possible risk factor for diabetes (19).
In the present study, levels of blood pressure, vitamin D, 
TG, and FBS were significantly higher in the patients than 
in the normal group. The study by Borzouei et al on 186 
adults, revealed that people with vitamin D deficiency had 
a higher chance of metabolic syndrome development, with 
significantly higher waist size, systolic blood pressure, 
and FBS in the patients than in the healthy group (20). 
Roshanzamir et al found that HDL-C had a significant, 
direct correlation with vitamin D level (21). Ford et 
al evaluated serum levels of vitamin D and metabolic 
syndrome in 8421 adults and found a significant, inverse 
correlation between serum vitamin D and TG and FBS 
levels and waist size. An inverse relationship was also 
shown between serum vitamin D levels and metabolic 
syndrome (16). Besides, Moy and Bulgiba investigated 
the relation of vitamin D with the prevalence of metabolic 
syndrome. They showed that people with lower levels of 
vitamin D had higher incidences of metabolic syndrome 
(22). However, in some studies, no significant correlations 
were found between vitamin D deficiency and metabolic 
syndrome components (15,23,24). The disparate results 
can be attributed to the role of vitamin D in 3% expression 
of the human genome, which may help explain the 
increased prevalence of metabolic syndrome in patients 
with vitamin D deficiency (25).
Conclusion
The results of this study suggest that examining the serum 
levels of vitamin D allows screening people at risk for 
metabolic syndrome development, especially in high-risk 
individuals. 
Limitations of our study
A limitation of this study was relatively small size studied 
population. Further investigation in this regard suggests.
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Table 3. Frequency distribution of vitamin D status in the studied groups
Vitamin D
Groups
Patients with metabolic syndrome Control (obese individuals without metabolic syndrome) Total
Deficient (<20 ng/mL) 58 (60.42%) 8 (8.33%) 66 (34.38%)
Insufficient (20-30 ng/mL) 25 (26.04%) 22 (22.92%) 47 (24.48%)
Sufficient  (30-100 ng/mL) 13 (13.54%) 64 (66.67%) 77 (40.10)
Toxicity (>100 ng/mL) 0 (0%) 2 (2.08%) 2 (1.04%)
Total 96 (100) 96 (100) 192 (100)
Table 4. Relationships between metabolic syndrome indicators and different levels of vitamin D in the subjects
Variables
Vitamin D
P value
<20 20-30 30-100 >100
HDL-C (mg/dL) 44.43  ±  5.69 48.19 ± 8.58 52.86 ± 13.54 50.5 ± 2.12 <0.001
TG (mg/dL) 172.34 ± 19.66 164.1 ± 22.89 149.1 ± 22.05 130.5 ± 6.39 <0.001
FBS (mg/dL) 122.39 ± 41.4 115.63 ± 47.3 100.9 ± 22.04 72.5 ± 2.12 0.002
Waist size (cm) 94.06 ± 11.33 95.52 ± 8.5 95.34 ± 8.44 94 ± 0.0 0.825
Blood pressure (mm Hg) 134.77 ± 17.96 132.6 ± 15.73 126.52 ± 16.19 140 ± 28.28 0.019
BMI (kg/m2) 27.88 ± 3.1 27.82 ± 2.26 27.87 ± 2.81 27.69 ± 1.13 0.999
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